TF CAR-NK cell therapy / Cartherics - LARVOL DELTA

Cartherics executes Option Agreement with The Ohio State University (Cartherics Press Release) - "Cartherics Pty Ltd...is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP) from The Ohio State University (Ohio State) covering tissue factor (TF) as a target for chimeric antigen receptor (CAR) natural killer (NK) cells. The Company will utilise its proprietary induced pluripotent stem cell (iPSC)-derived NK cells to conduct the evaluation. Subject to the results, Cartherics will then exercise the option to negotiate a commercial licence to the IP....Cartherics will generate CAR constructs based on the Ohio State IP and insert them into its iPSC-derived NK cells. The resultant TF CAR-NK cells will then be assessed for in vitro and in vivo efficacy against relevant human cancer cell lines."

Licensing / partnership • Oncology